title: [Postoperative radiotherapy of prostate cancer].
abstract: After radical prostatectomy, the risk of biological recurrence at 5 years varies from 10 to 40 % and this natural evolution of the disease has led radiation therapy being proposed as a supplement to surgery. When the recurrence risk is essentially local, supplementary radiotherapy is justified in the aim of improving biological recurrence-free survival, local control, metastasis-free survival and specific and global survival, while respecting patient quality of life. Three recent studies, EORTC 22911, ARO 9602 and SWOG 8794 found a similar advantage for biological recurrence-free survival without higher major additional toxicity. However, only the SWOG 8794 study found a significant improvement for metastasis-free survival and global survival. In an adjuvant setting, the optimal moment to propose this postoperative radiotherapy remains uncertain: should it be proposed systematically to all pT3 R1 patients, running the risk of pointlessly treating patients who will never recur, or should it only be proposed at recurrence? The GETUG AFU 17 trial will provide answers to the question of the optimal moment for postoperative radiotherapy for pT3-4 R1 pN0 Nx patients with the objective of comparing an immediate treatment to a differed early treatment initiated at biological recurrence.
authors.affiliation: Service de Radiothérapie, Centre Régional de Lutte Contre le Cancer, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux cedex, France. richaud@bergonie.org
authors.forename: P
authors.initials: P
authors.lastname: Richaud
authors.forename: P
authors.initials: P
authors.lastname: Sargos
authors.forename: B
authors.initials: B
authors.lastname: Henriques de Figueiredo
authors.forename: I
authors.initials: I
authors.lastname: Latorzeff
authors.forename: P
authors.initials: P
authors.lastname: Mongiat-Artus
authors.forename: N
authors.initials: N
authors.lastname: Houédé
authors.forename: L
authors.initials: L
authors.lastname: Salomon
authors.forename: H
authors.initials: H
authors.lastname: Wallerand
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000601:surgery*; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D015182:Lymphatic Irradiation; D008207:Lymphatic Metastasis; D008297:Male; D015337:Multicenter Studies as Topic / Q000379:methods / Q000706:statistics & numerical data; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D011832:Radiation Injuries / Q000517:prevention & control; D018714:Radiotherapy, Adjuvant / Q000379:methods; D050397:Radiotherapy, Intensity-Modulated; D012107:Research Design; D016896:Treatment Outcome; D019564:Unnecessary Procedures